(Q83791245)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Genetic heterogeneity and cancer drug resistance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Nicholas C Turner

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Jorge S Reis-Filho

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

30 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

e178-85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

The evolving war on cancer

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Human cancers express mutator phenotypes: origin, consequences and targeting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Genome remodelling in a basal-like breast cancer metastasis and xenograft

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Genetic variegation of clonal architecture and propagating cells in leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Genomic instability--the engine of tumorigenesis?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Patterns of somatic mutation in human cancer genomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

A small-cell lung cancer genome with complex signatures of tobacco exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Signatures of mutation and selection in the cancer genome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Genomic instability--an evolving hallmark of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

A comprehensive catalogue of somatic mutations from a human cancer genome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

A non-genetic route to aneuploidy in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Aneuploidy drives genomic instability in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Mutational inactivation of STAG2 causes aneuploidy in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Genetic Interactions in Cancer Progression and Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Complex landscapes of somatic rearrangement in human breast cancer genomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Paradoxical relationship between chromosomal instability and survival outcome in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Metastatic behavior of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Tumor size and survival in breast cancer--a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Environment-mediated drug resistance: a major contributor to minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Evolutionary dynamics of cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Stem cells, cancer, and cancer stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Breast-cancer stem cells-beyond semantics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Efficient tumour formation by single human melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Resistance to therapy caused by intragenic deletion in BRCA2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Human cancers express a mutator phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

The role of cytoreductive/debulking surgery in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

CyberKnife stereotactic radiosurgery for intracranial neoplasms, with a focus on malignant tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970335-7

7 January 2021

10.1016/S1470-2045(11)70335-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469128%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference